Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlights eight publications in international journals that have confirmed that kinase-activity...Read More
PRECISE, a Dutch-Swiss consortium between PamGene International B.V., Novigenix SA and Radboud University Medical Center, has been awarded a Eurostars grant of up to €1 million to develop a novel...Read More
Kinases have been running like a thread through Dr. Julhash Uddin Kazi’s career. They also played the lead part in the Lund University’s Associate Professor of Molecular Medicine’s recent Nature...Read More
PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, today announced it has received extension of its ISO 13485:2016 certification. The...Read More
The 1st Annual Cancer Bioinformatics Symposium at the University of Toledo College of Medicine and Life Sciences will take place February 5th. The full day, online event champions collaboration between...Read More
Journal for ImmunoTherapy of Cancer published the results of a study focusing on the potential of kinase activity profiling to predict the response of Melanoma and Non Small Cell Lung...Read More
“I’m focused on continuous improvement of therapeutic strategies and to translate these into solutions for patients suffering from lung diseases,” tells Dr. Astrid Weiß, post doc. at the Biomedical Research...Read More
“When you combine traditional laboratory techniques with advanced computational biology techniques, you can significantly improve the quality and quantity of your research and produce experimental results that give you much...Read More
Blood-based biomarker test has the potential to decrease the number of both over- and undertreated patients improving overall response rate, reduce unnecessary side effects and help saving costs. PamGene, a...Read More
PamGene, a biotech and services company focused on the development and commercialization of multiple novel biomarker panels for patient stratification in immuno-oncology, is pleased to announce that new data from...Read More
